Note 18 - Supplementary Financial Information (unaudited) (Detail) - Selected financial information for the quarterly periods noted (USD $)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Revenues	$ 148,489,000	$ 128,568,000
Gross profit	57,871,000	62,553,000
Net income	105,442,000	12,365,000
Net income per share (basic) (in Dollars per share)	$ 1.59	$ 0.19
Net income per share (diluted) (in Dollars per share)	$ 1.55	$ 0.18
Basic (in Shares)	66,487,470	65,122,240
Diluted (in Shares)	68,178,355	67,907,263
Global Division [Member] | Rx Partner [Member]
Sales revenue net	3,114,000	2,978,000
Global Division [Member] | Other Revenues [Member]
Sales revenue net	737,000	4,076,000
Global Division [Member] | Chargeback Reserve [Member]
Sales allowances goods	64,345,000	39,155,000
Global Division [Member] | Rebate Reserve [Member]
Sales allowances goods	30,572,000	20,589,000
Global Division [Member] | Other Credits [Member]
Sales allowances goods	5,160,000	10,045,000
Global Division [Member]
Sales revenue goods gross	197,956,000	185,671,000
Sales revenue goods net	97,785,000	116,211,000
Revenues	101,636,000	123,265,000
Product Returns	94,000	(329,000)
Impax Division [Member] | Rebate Reserve [Member]
Sales allowances goods	6,236,000
Impax Division [Member] | Other Credits [Member]
Sales allowances goods	7,255,000
Impax Division [Member]
Sales revenue goods gross	69,292,000
Sales revenue goods net	46,521,000
Sales revenue net	332,000	5,303,000
Revenues	46,853,000	5,303,000
Product Returns	1,490,000
Impax Division [Member] | Chargeback Reserve [Member]
Sales allowances goods	$ 7,790,000